Is Eisai Co Ltd (ADR) (ESAIY) a Good Dividend Stock?
Learn more about Eisai Co Ltd (ADR)'s (ESAIY) dividend history and yield. Also, check out how they are graded based on valuation, growth and strength.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Eisai Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals in Japan. The company operates through pharmaceuticals business and other business segments. It offers Lenvima, a multi-kinase inhibitor which is involved in tumor angiogenesis or tumor malignancy; LEQEMBI, a humanized IgG1 monoclonal antibody against amyloid-beta (Aß) protofibrils; and Dayvigo, a novel small molecule compound. The company also provides prescription drugs; and over-the-counter drugs, as well as focuses on neurology and oncology, and other therapeutic areas. It operates in Europe, the Middle East, Africa, Russia, Oceania, the Americas, China, East Asia, the Global South, and internationally. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
Commentary & Analysis
Is Eisai Co Ltd (ADR) (ESAIY) Stock a Good Investment?
Learn more about Eisai Co Ltd (ADR)'s (ESAIY) stock grades for Momentum and Growth and determine whether this Pharmaceuticals stock meets your investment needs.Jenna Brashear
Financial Summary
| Share Statistics | ESAIY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $8,550.8 | $579.1 | 75% |
|
| Shares Out (Mil) | 1.8 | 43.0 | 7% |
|
| Institutional Ownership | 49.8% | 84.3% | 26% |
|
| Float (Mil) | 266.8 | 46.8 | 78% |
|
| Beta | -0.15 | 0.62 | 4% |
|
| Avg Daily Volume (000s) | 90 | 285 | 35% |
|
| Price Change (52-week) |
6.7% | 63.8% | 51% |
|
| Growth | ESAIY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (2.3%) | 6.7% | 12% |
|
| Net Income (5yr) | (8.6%) | (1.4%) | 30% |
|
| EPS (5yr) | (8.3%) | 14.9% | 22 |
|
| Dividends (5yr) | (7.0%) | 0.0% | 79% |
|
| Cash Flow (5yr) | (30.1%) | (14.9%) | 19% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | ESAIY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $5,191 | $272 | 75% |
|
| Net Income (TTM) (Mil) | $243 | ($11) | 70% |
|
| EPS (TTM) | $0.860 | ($0.500) | 59% |
|
| Operating Cash Flow (TTM) (Mil) | $386 | ($6) | 68% |
|
| Net Cash Flow (TTM) (Mil) | ($774) | $4 | 4% |
|
| Long-Term Debt (Q1) (Mil) | $848 | $7 | 65% |
|
| Enterprise Value (Q1) (Mil) | $6,716 | $522 | 67% |
|
| Valuation | ESAIY | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.73 | na |
|
| P/E | na | 20.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | ESAIY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 76.8% | 65.9% | 87% |
|
| Net Margin | 4.7% | 0.7% | 47% |
|
| ROA | 2.6% | (24.6%) | 59% |
|
| ROE | 4.2% | (19.7%) | 42% |
|
| Liabilities to Assets | 36.2% | 35.5% | 27% |
|
| F-Score | na | 3 | na |
|
Eisai Co., Ltd. did not pass any screens on 7/31/2026.
